Immunex

Immunex was a pioneering biotechnology company based in Seattle, Washington, that focused on the discovery and development of therapeutic products for cancer, inflammation, and infectious diseases. The company is most famous for the development of Enbrel (etanercept), a landmark recombinant fusion protein that transformed the treatment landscape for rheumatoid arthritis and other autoimmune conditions. Founded in 1981, Immunex established itself as a leader in cytokine biology and receptor-based drug design. Its success led to its acquisition by Amgen in 2002 for approximately $16 billion, which at the time was one of the largest acquisitions in the history of the biotechnology industry. The company's legacy continues through its portfolio of approved biologics and its foundational research in immunology. Today, its former headquarters and research facilities remain a significant part of the Seattle biotech ecosystem.